SCHEMBL4495899

SCHEMBL4495899

Oc1ccc2[nH]c(-c3ccccc3-c3nc4cc(O)ccc4[nH]3)nc2c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AMY1A P0DUB6 3/20 0.53
NPC1 O15118 7/20 0.52
RAB9A P51151 7/20 0.52
ALDH1A1 P00352 6/20 0.52
SMN1; SMN2 Q16637 5/20 0.52
NPSR1 Q6W5P4 5/20 0.52
KDM4E B2RXH2 5/20 0.52
HPGD P15428 4/20 0.52
GAA P10253 3/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
GLA P06280 2/20 0.52
MAPT P10636 2/20 0.52
F7 P08709 1/20 0.50
CBFB Q13951 1/20 0.49
PKM P14618 2/20 0.49
HSD17B10 Q99714 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GPR55 Q9Y2T6 1/20 0.49
HTT P42858 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14601535 0.87 AMY1A (0.51) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2324234 0.84 NPC1 (0.62) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2310193 0.83 RAB9A (0.44) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL7136331 0.81 NPC1 (0.51) NPC1RAB9AALDH1A1SMN1; SMN2NPSR1
SCHEMBL6282502 0.81 GAA (0.53) NPC1RAB9AALDH1A1SMN1; SMN2KDM4E
SCHEMBL2310794 0.81 NPC1 (0.46) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2310791 0.81 NPC1 (0.46) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL5579984 0.80 CHEK1 (0.59) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2311266 0.80 HSP90AB1 (0.41) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2
SCHEMBL2311273 0.80 HSP90AB1 (0.41) AMY1ANPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7482373-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2009-01-27 US disclosed
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2007-02-01 US disclosed
US-7132439-B2 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2006-11-07 US disclosed
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators ICAGEN, INC. (US) 2004-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070027200-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 AMY1A 4827/4885NPC1 1216/4885RAB9A 3054/4885
US-20040029925-A1 Bis-benzimidazoles and related compounds as potassium channel modulators KCNJ2, KCNA3, KCNB2 AMY1A 4827/4885NPC1 1216/4885RAB9A 3054/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.